Brexpiprazole in Borderline Personality Disorder

Summary

Brexpiprazole in Borderline Personality Disorder is a clinical trial^[1].

Key Facts

• Brexpiprazole in Borderline Personality Disorder is in the country of United States^[2].
• Brexpiprazole in Borderline Personality Disorder's instance of is recorded as clinical trial^[3].
• Brexpiprazole in Borderline Personality Disorder's start time is recorded as +2018-11-26T00:00:00Z^[4].
• Brexpiprazole in Borderline Personality Disorder's end time is recorded as +2020-04-30T00:00:00Z^[5].
• Brexpiprazole in Borderline Personality Disorder's sponsor is recorded as University of Chicago^[6].
• Brexpiprazole in Borderline Personality Disorder's main subject is recorded as borderline personality disorder^[7].
• Brexpiprazole in Borderline Personality Disorder's number of participants is recorded as {'unit': '1', 'amount': '+80'}^[8].
• Brexpiprazole in Borderline Personality Disorder's title is recorded as A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.^[9].
• Brexpiprazole in Borderline Personality Disorder's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Brexpiprazole in Borderline Personality Disorder's ClinicalTrials.gov ID is recorded as NCT03418675^[11].
• Brexpiprazole in Borderline Personality Disorder's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• Brexpiprazole in Borderline Personality Disorder's research intervention is recorded as brexpiprazole^[13].
• Brexpiprazole in Borderline Personality Disorder's clinical trial phase is recorded as phase II clinical trial^[14].
• Brexpiprazole in Borderline Personality Disorder's research site is recorded as University of Chicago^[15].
• Brexpiprazole in Borderline Personality Disorder's study type is recorded as interventional study^[16].